– This trial, conducted in patients with type 2 diabetes, compared three doses each of Dance 501 inhaled insulin and subcutaneous insulin lispro – June 04, 2019 08:30 AM Eastern Daylight Time Dance Biopharm Holdings, Inc., a privately-held clinical stage...
Study successfully met its endpoints and provides basis for pivotal Phase 3 trial Syntrix Pharmaceuticals today announced the publication of positive results from two consecutive randomized and double-blind controlled trials that compared desmetramadol to placebo and...
Victory Nutrition International, Inc (“VNI”) announces Prodovite VMP35 MNC, a novel iron-free supplement, enhances cytoprotection against anemia in human subjects: a novel hypothesis. The clinical study paper is published in Food & Nutrition Research,...
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting CD16 and CD19 in patients with lymphoma CULVER CITY, CA, USA I June 03, 2019 I NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,...
Mataró, Barcelona, Spain and Charleroi, Belgium, June 4, 2019 – Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone...
Incyte (Nasdaq:INCY) today announced that the first patient has been treated in FIGHT-302, an open-label Phase 3 study evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, compared to gemcitabine with cisplatin...
Email
Text